Want to see SE:SOBI full AI Analyst Report?
SOBI Stock Chart & Stats
kr388.60
-kr5.60(-1.80%)
At close: 4:00 PM EST
kr388.60
-kr5.60(-1.80%)
Day’s Range― - ―
52-Week Rangekr261.20 - kr483.80
Previous CloseN/A
Volume57.50K
Average Volume (3M)396.16K
Market Cap
kr165.19B
Enterprise Valuekr170.43B
Total Cash (Recent Filing)kr940.00M
Total Debt (Recent Filing)kr19.06B
Price to Earnings (P/E)181.0
Beta1.04
Next Earnings
Jul 16, 2026EPS Estimate
3.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.65
Shares Outstanding357,412,840
10 Day Avg. Volume356,894
30 Day Avg. Volume396,160
Financial Highlights & Ratios
PEG Ratio-2.73
Price to Book (P/B)3.04
Price to Sales (P/S)4.06
P/FCF Ratio13.44
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
kr495.00Price Target Upside27.38% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)18.34
Revenue Forecast (FY)kr32.11B
Bulls Say, Bears Say
Bulls Say
Revenue MomentumSobi's strong trailing-twelve-month revenue momentum reflects durable demand for its rare-disease therapies and improving market penetration. Persistent top-line growth supports multi-quarter revenue visibility, funds R&D and commercialization, and underpins long-term strategic investments in core franchises.
Cash GenerationConsistent positive operating and free cash flow indicates the business converts sales into cash reliably, enabling self-funded R&D, commercial expansion and debt servicing. Cash-backed earnings reduce reliance on external financing and enhance resilience across industry cycles.
Balance Sheet FlexibilityA low debt-to-equity position gives Sobi financial flexibility to invest in growth, absorb regulatory or reimbursement shifts, and pursue partnerships. Manageable leverage supports durable capital allocation optionality and reduces short-to-medium-term refinancing pressure.
Bears Say
Weak Net ProfitabilitySharp deterioration in net margins and very low profitability signal structural pressure below the operating line—higher financing, tax, or one-off charges—reducing returns on capital. Persistently weak net income limits reinvestment, dividend capacity and long-term shareholder returns.
Free Cash Flow VolatilityRecent decline and historical volatility in free cash flow undermine cash predictability. Inconsistent FCF raises risk that funding for R&D or commercialization may require external financing in tougher periods, increasing exposure to market or refinancing conditions.
Rising Reported DebtA notable increase in total debt amid weakened earnings reduces cushioning provided by previously low leverage. Higher absolute debt elevates interest and refinancing risk, limiting strategic flexibility and potentially constraining M&A or investment when profits remain depressed.
SOBI FAQ
What was Swedish Orphan Biovitrum AB’s price range in the past 12 months?
Swedish Orphan Biovitrum AB lowest stock price was kr261.20 and its highest was kr483.80 in the past 12 months.
What is Swedish Orphan Biovitrum AB’s market cap?
Swedish Orphan Biovitrum AB’s market cap is kr165.19B.
When is Swedish Orphan Biovitrum AB’s upcoming earnings report date?
Swedish Orphan Biovitrum AB’s upcoming earnings report date is Jul 16, 2026 which is in 10 days.
How were Swedish Orphan Biovitrum AB’s earnings last quarter?
Swedish Orphan Biovitrum AB released its earnings results on Apr 28, 2026. The company reported kr3.81 earnings per share for the quarter, beating the consensus estimate of kr3.633 by kr0.177.
Is Swedish Orphan Biovitrum AB overvalued?
According to Wall Street analysts Swedish Orphan Biovitrum AB’s price is currently Undervalued.
Does Swedish Orphan Biovitrum AB pay dividends?
Swedish Orphan Biovitrum AB does not currently pay dividends.
What is Swedish Orphan Biovitrum AB’s EPS estimate?
Swedish Orphan Biovitrum AB’s EPS estimate is 3.35.
How many shares outstanding does Swedish Orphan Biovitrum AB have?
Swedish Orphan Biovitrum AB has 357,412,840 shares outstanding.
What happened to Swedish Orphan Biovitrum AB’s price movement after its last earnings report?
Swedish Orphan Biovitrum AB reported an EPS of kr3.81 in its last earnings report, beating expectations of kr3.633. Following the earnings report the stock price went up 1.204%.
Which hedge fund is a major shareholder of Swedish Orphan Biovitrum AB?
Currently, no hedge funds are holding shares in SE:SOBI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Haematology, Immunology, and Specialty Care. It offers Alprolix for haemophilia B; ALTUVOCT for the treatment and prophylaxis of bleeding in patients with haemophilia A; Aspaveli/Empaveli for treating adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet for the treatment of immune thrombocytopenia and thrombocytopenia; Elocta/Eloctate for the treatment and prophylaxis of bleeding in patients with haemophilia A; Gamifant for treating hemophagocytic lymphohistiocytosis; Kineret for the treatment of cryopyrin-associated periodic syndrome, rheumatoid arthritis, familial Mediterranean fever, deficiency of interleukin-1 receptor antagonist, and systemic juvenile idiopathic arthritis; Orfadin for hereditary tyrosinemia type 1 and alkaptonuria; Synagis for the prevention of serious lower respiratory tract infection caused by respiratory syncytial virus in infants and young children; VONJO, a kinase inhibitor indicated for the treatment of post-polycythemia vera or post-essential thrombocythemia myelofibrosis; and Zynlonta for treating adult patients with relapsed or refractory diffuse large and high grade B-cell lymphoma. The company also provides other medicines, such as Akynzeo, Jyseleca, Tegsedi, and Waylivra, as well as develops drug substances for ReFacto AF/Xyntha for Pfizer. The company has collaboration agreements with Sanofi, Apellis Pharmaceuticals, Inc., ADC Therapeutics SA, and Cartesian Therapeutics, Inc. The company was incorporated in 1939 and is headquartered in Stockholm, Sweden.
SOBI Stock 12 Month Forecast
Average Price Target
kr495.00
▲(27.38% Upside)
Technical Analysis
Orexo AB
―
AlzeCure Pharma AB
―
Klaria Pharma Holding AB
―
Nanexa AB
―
Enorama Pharma AB
―
Options Prices
Currently, No data available
---